Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.

ABSTRACT: BACKGROUND:Next-generation sequencing (NGS) of the rearranged immunoglobulin heavy-chain gene has emerged as a highly sensitive method to detect minimal residual disease (MRD) in B acute lymphoblastic leukemia/lymphoma (B-ALL). However, a sensitive and easily implemented NGS methodology for routine clinical laboratories is lacking and clinical utility of NGS-MRD surveillance in a post-remission setting to predict clinical relapse has not been determined. METHODS:Here we described a simple and quantitative NGS platform and assessed its performance characteristics, quantified NGS-MRD levels in 122 B-ALL samples from 30 B-ALL patients, and explored the clinical merit of NGS-based MRD surveillance. RESULTS:The current NGS platform has an analytic sensitivity of 0.0001% with excellent specifici

SUBMITTER: Cheng S 

PROVIDER: S-EPMC6103872 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature